Introduction

While various clinical and experimental immunosuppressive therapies promote the acceptance of transplanted organs, it is intuitive that graft acceptance is likely achieved by distinct immunologic mechanisms depending upon the therapy. The nature of the immune mechanisms responsible for graft acceptance likely reflects various immune deviations induced by different therapies that may vary in strength and resistance to reversal. A better understanding of immune parameters responsible for maintaining various forms of graft acceptance would facilitate the development of strategies aimed at achieving vigorous and nonreversible transplant acceptance. For example, we have previously reported that inductive therapy with either anti-CD4 (1,2) or anti-CD40L (2,3) monoclonal antibodies (mAb) markedly prolongs cardiac allograft survival. However, at 60 days posttransplant, functioning allografts in anti-CD4-treated recipients develop signs of chronic rejection (CR) including transplant-associated vasculopathy (TAV) and interstitial collagen deposition (4), while allografts in anti-CD40L-treated recipients do not (3). These differences correlate with the intragraft expression of TGFb and induction of connective tissue growth factor (CTGF) in recipients treated with anti-CD4 (that develop CR), but not in recipients treated with anti-CD40L (that do not develop CR) (5). This study explored additional immunologic differences that result from these inductive mAb therapies and sheds further light on the mechanisms of action underlying the resulting states of graft acceptance. To this end, an adoptive transfer system revealed differential cytokine production by graft-reactive T cells as well as distinct sensitivities to reversal of allograft acceptance. In this system, cells obtained from anti-CD4-treated primary recipients (anti-CD4 cells) were skewed toward a Th2 phenotype and failed to mediate rejection following adoptive transfer into secondary severe combined immunodeficiency (SCID) allograft recipients. In contrast, cells from anti-CD40L-treated recipients (anti-CD40L cells) exhibited a Th1 phenotype and mediated rejection following transfer. Thus, the robust and nonreversible graft acceptance mediated by anti-CD4 cells correlated with altered T-cell function whereas anti-CD40L cells maintained the functional capacities of naïve T cells.
Materials and Methods
Mice
Female wild-type (WT) and SCID C57BL/6 (H-2 b ) and BALB/c (H-2 d ) mice
were purchased from The Jackson Laboratories (Bar Harbor, ME) 
Real-time PCR for intragraft IFNc and IL-4 expression
Results
While inductive treatment with either anti-CD4 or anti-CD40L mAb results in prolonged allograft survival, treatment with anti-CD4 results in CR while treatment with
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anti-CD40L does not (3-5). The development of CR is associated with the intragraft expression of TGFb and CTGF in recipients treated with anti-CD4 and the absence of CR correlates with the lack of expression of these cytokines in recipients treated with anti-CD40L (5). This study explores additional immune parameters that are associated with prolonged allograft survival under these conditions.
Donor-reactive precursor cells are detectable in mice bearing long-term allografts
In Figure 1 , we employed ELISPOT (8) ( n = 3 ) ( n = 2 ) ( n = 8 ) ( n = 7 ) ( n = 7 ) ( n = 1 ) ( n = 1 )
Indicates grafts were functioning at time of sacrifice Figure 3A) . Figure 2 and
Wood et al.
assessed for primed donorreactive Th1 and Th2 responses by ELISPOT. Data represent the average of responses + SEM for 6-21 individual SCID recipients. Where indicated, 7 SCID recipients of anti-CD4 cells were treated with 1-mg anti-IL-4 mAb three times per week for 30 days. All 7 allografts in anti-IL-4 mAb-treated recipients continued to function normally until the termination of the experiment. Panel B: T-cell subsets were depleted from splenocyte populations with immunomagnetic beads before culture in ELISPOT assays to determine the contributions CD4+ and CD8+ T cells to cytokine profiles. Bars represent the average responses + SEM of 5-8 separate experiments. Panel C: Intragraft IFNc and IL-4 gene expression was assessed by real-time PCR. Each data point represents the cytokine gene expression level of an individual allograft. Horizontal bars depict the mean expression level for each group.
The contributions of T-cell subsets to cytokine profiles were determined by depleting CD4+ and CD8+ cells prior to addition to the ELISPOT assays (Figure 3B). When CD4+ cells were depleted, the profiles of cytokine production were maintained for both anti-CD4 and anti-CD40L cells. When CD8+ cells were depleted prior to ELISPOT, Th2 responses were induced in all cell populations, in keeping with previous reports that depleting CD8+ cells results in Th2 responses (i.e. Reference 10). These data indicate that CD8+ cells influence Th1/Th2 balance in this system
by suppressing CD4+ Th2 function. We also asked whether T-cell priming was evident early posttransplantation in primary allograft recipients ( Figure 4A ). Low, albeit detectable Th1 and Th2 priming was observed in both groups at day 10 posttransplant. Figure 5A, Figure 5A (12) in keeping with the idea that anti-CD40L mAb contributes to the elimination of effector cells. (1, 10) . These CD8+ cells produce IFNc and little IL-4 (9, 10, 18) , which suggested that Th1 were critical to the rejection process and that inducing Th2 may promote graft acceptance (reviewed in Reference 14) . However, depleting CD8+ cells induces Th2 that recruit granulocytes resulting in a nonclassical form of rejection (10, 19, 20) 
We next asked whether the cytokine profiles assessed by ELISPOT analyses of splenocytes were reflective of
Differential Maintenance of Allograft Acceptance cytokine profiles within the transplant. However, ELISPOT analyses were precluded due to insufficient numbers of graft-infiltrating cells. Hence, we performed real-time PCR to quantify intragraft IFNc and IL-4 expression levels in the allografts of SCID recipients of naïve, anti-CD4 or anti-CD40L cells (Figure 3C). IFNc expression levels were significantly higher in the grafts of SCID recipients of anti-CD40L or naïve cells relative to recipients of anti-CD4 cells. Similarly, IL-4 expression levels were significantly higher in the grafts of recipients of anti-CD4 cells when compared to recipients of anti-CD40L or naïve cells. Thus, the ELISPOT data obtained from splenocytes reflected the patterns of cytokine gene expression within the allografts.
Donor-reactive T-cell priming following inductive anti-CD4 and anti-CD40L in primary allograft recipients The finding that anti-CD4 and anti-CD40L cells transferred distinct cytokine profiles to secondary SCID allograft recipients suggested that these cell populations experienced distinct events in the primary allograft recipients. The anti-CD4 mAb GK1.5 depletes peripheral CD4+ cells (11). When mice are treated with our inductive anti-CD4 regimen, CD4+ cells are transiently depleted and begin to repopulate the periphery between 3 and 4 weeks (4,7). Hence, we assessed donor-reactive T-cell priming in anti-CD4-treated primary allograft recipients on day 30 posttransplant and compared these responses to their anti-CD40L counterparts (Figure 4B). While responses in anti-
Thus, T-cell priming was short-lived in primary allograft recipients treated with anti-CD40L mAb. This in vivo finding is in keeping with the in vitro observation of Blair et al. (12) who reported that cross-linking CD40L results in cytokine production followed by apoptosis of activated T cells.
Assessing the effects of anti-CD40L mAb on donor-reactive T cells It has been reported that memory, but not naïve T cells are resistant to the suppressive effects of anti-CD40L mAb (13). Therefore, if anti-CD40L cells are maintained in a naïve state, then rejection following transfer of these cells into secondary SCID recipients should be ablated by anti-CD40L mAb treatment of these SCID mice. To this end, SCID allograft recipients were infused with naïve or anti-CD40L cells and treated with anti-CD40L or control hIgG. As shown in
and B). Thus, activated effector cells were targeted by anti-CD40L mAb, while memory cells were not. An alternate explanation for this observation is that effector cells, but not memory cells, undergo activation-induced cell death upon adoptive transfer into SCID allograft recipients as opposed to being controlled by anti-CD40L mAb. While we cannot definitively rule out this possibility, it should be noted that perturbation of CD40L on activated T cells has been reported to induce apoptosis
Discussion
Multiple effector mechanisms of allograft rejection exist (reviewed in References 14-17). For example, unmodified cardiac allograft rejection is characterized by a prominent CD8+ T-cell response
. Similar observations have been made in liver transplant patients undergoing acute rejection (21). Further, complete elimination of IFNc results in IL-4 production by CD8+ cells and a granulocytic infiltrate that is not controlled by depleting CD4+ cells or anti-CD40L
therapy (2) . Thus, while IFNc may contribute to rejection, this cytokine also appears to be required for allograft acceptance under certain conditions. These observations point to a delicate balance between allograft rejection and acceptance. (2) Since there are multiple effector mechanisms of rejection (reviewed in , it comes as no surprise that sustained allograft 'tolerance' has been difficult to achieve (22, 23) . While various therapies promote allograft 'acceptance' (reviewed in (Figure 1) (9) . Similarly, Bass et al. (29) References 36, [38] [39] [40] (45) (46) (47) (48) . CD40L expression is enhanced and prolonged on Th1, but not Th2 (49) . Indeed, the effector cells used in this study were generated from unmodified allograft recipients and exhibit a polarized Th1 phenotype (Figure 1 ) (9) that may facilitate removal by anti-CD40L mAb in vivo. This notion is supported by reports that C is required for optimal effectiveness of anti-CD40L mAb in vivo (50, 51) .
Treg play an important role in allograft acceptance and maintenance (reviewed in References 25, 52 and 53) and it is likely that adaptive Treg are generated by both anti-CD4 and anti-CD40L therapies. Indeed, quiescent precursor donor-reactive cells are present in long-term allograft bearing mice that received either of these inductive regimens (Figure 1) (3,7) 
